Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13687191 | 0.74 | ALOX15 (0.40) | TDP1ALOX15TYMS | |
| SCHEMBL13687197 | 0.73 | ALOX15 (0.34) | TDP1ALOX15 | |
| Anthraquinone SCHEMBL1332299 | 0.71 | MEN1 (0.37) | — | |
| SCHEMBL13687194 | 0.69 | ALOX15 (0.36) | TDP1ALOX15TYMS | |
| SCHEMBL3993249 | 0.67 | TDP1 (0.59) | TDP1ALOX15TYMSALDH1A1KDM4E | |
| Anthraquinone SCHEMBL3419643 | 0.67 | MEN1 (0.63) | TDP1ALOX15ALDH1A1KDM4EHPGD | |
| Phthalic Anhydride SCHEMBL220 | 0.65 | TDP1 (1.00) | TDP1ALOX15TYMSALDH1A1KDM4E | |
| Phthalic Anhydride SCHEMBL380499 | 0.65 | TDP1 (1.00) | TDP1ALOX15TYMSALDH1A1KDM4E | |
| Phthalic Anhydride SCHEMBL29356227 | 0.65 | TDP1 (1.00) | TDP1ALOX15TYMSALDH1A1KDM4E | |
| Anthraquinone SCHEMBL29831102 | 0.64 | MEN1 (0.57) | TDP1ALOX15ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064004-A1 | ISOTOPOLOGUES OF THALIDOMIDE | CELGENE CORPORATION | 2012-03-15 | — | — | US | disclosed |
| US-20110282587-A1 | COMPUTER READABLE STORAGE MEDIUMS, METHODS AND SYSTEMS FOR NORMALIZING CHEMICAL PROFILES IN BIOLOGICAL OR MEDICAL SAMPLES DETECTED BY MASS SPECTROMETRY | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| US-20080312318-A1 | DEUTERIUM-ENRICHED ESCITALOPRAM | PROTIA, LLC (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312318-A1 | DEUTERIUM-ENRICHED ESCITALOPRAM | SLC6A4, SLC6A3, SLC6A2 | TDP1 2088/4885ALOX15 3521/4885TYMS 3831/4885 |
| US-20120064004-A1 | ISOTOPOLOGUES OF THALIDOMIDE | CDK4, FKBP8, FKBP1A | TDP1 963/4885ALOX15 4164/4885TYMS 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.